- Finance
- Watchlists
- My Portfolio
- Cryptocurrencies
- Yahoo Finance Plus
- Screeners
-
Markets
-
Options: Highest Open up InvolvementOptions: Highest Open Interest
-
Options: Highest Implied VolatilityOptions: Highest Implied Volatility
-
- News
- Personal Finance
-
Videos
-
Influencers with Andy SerwerInfluencers with Andy Serwer
-
Yahoo Finance All Markets SummitYahoo Finance All Markets Pinnacle
-
America: Back in BusinessAmerica: Dorsum in Business
-
- Yahoo U
- Industries
- Tech
- Contact Us
U.S. markets close in vi hours x minutes
-
S&P 500
-
Dow 30
-
Nasdaq
-
Russell 2000
-
Crude Oil
-
Gold
-
Argent
-
EUR/USD
-
ten-Yr Bond
-
GBP/USD
-
USD/JPY
-
BTC-USD
-
CMC Crypto 200
-
FTSE 100
-
Nikkei 225
-
Gilead’s stock jumps 5% after setting patent case related to HIV therapies
Shares of Gilead Sciences Inc. were upwards five.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said information technology agreed to a non-exclusive license with several generic drug manufacturers – Cipla Ltd. , Lupin Ltd. , Apotex Inc., Macleods Pharmace
-
Nio’southward Sales Are Still Growing, But That’s Non Enough for the Stock
Nio (NYSE: NIO) recently reported its second-quarter results, and there were a couple of things the company should be proud of. Mainly, the company’s acquirement and vehicle sales saw significant increases from the year-agone quarter. In the recent past, climbing revenue and rising vehicle sales would accept likely sparked positive sentiment amidst electric vehicle investors.
-
3 Stocks Expecting Adept News From the FDA
Good news from the Food and Drug Assistants (FDA) tin send biotech stocks into the stratosphere. Patrick Bafuma (Mirati Therapeutics): One company that has to be champing at the flake to get FDA approval is Mirati Therapeutics, with its lead drug adagrasib.
-
Bristol Myers Stock Jumps equally U.Southward. Approves Psoriasis Drug
Shares of drugmaker Bristol Myers Squibb rose 7% in premarket trading Monday after it said the Food and Drug Administration canonical a key medication. The U.Due south. regulator approved the Bristol Myer (ticker: BMY) drug Sotyktu, an oral handling for psoriasis. Investors had been concerned that approval of Bristol Myers’southward handling would require a caution on the packaging of increased risks for other issues such equally heart illness or other side furnishings known every bit a black box alarm.
-
Reddit’s WallStreetBets is Buying These x Stocks in September
In this article, we will look at the 10 stocks that Redditors of WallStreetBets are buying in September. If you want to explore more stocks that Redditors are bullish on in September, you lot tin can as well accept a look at Reddit’s WallStreetBets is Buying These 5 Stocks in September. WallStreetBets became popular afterwards a group of […]
-
Is a Mega-Merger Betwixt Tilray and SNDL Inevitable?
Many businesses are struggling to abound, and pooling resource together tin be the best fashion to increase market share and generate efficiencies. Two cannabis companies that I can definitely encounter crossing paths in the virtually future are SNDL (NASDAQ: SNDL) and Tilray Brands (NASDAQ: TLRY). Both companies are fighting for market share, and that could intensify in the futurity, specially equally they continue to pursue acquisitions.
-
3 No-Brainer Oil Stocks to Buy in September
Oil prices have been all over the map this year. Oil’s next pace is anyone’due south guess. 3 oil companies that our free energy contributors call up look similar no-brainer investments in the current environment are TotalEnergies (NYSE: TTE), Chevron (NYSE: CVX), and ExxonMobil (NYSE: XOM).
-
-
-
x Best Penny Stocks to Purchase in September
In this commodity, we will take a look at the x all-time penny stocks to buy in September. If you want to skip our word on the electric current United states economic state of affairs, go directly to the five All-time Penny Stocks to Buy in September. The US equity markets have been experiencing a sell-off in the past three […]
-
The Next Bull Marketplace Is Coming: 2 Growth Stocks Down 68% and 74% to Purchase Now
The tech-heavy Nasdaq Composite is currently 24% off its high, putting the index in behave market place territory, and many individual stocks take fallen fifty-fifty farther. For example, Roku (NASDAQ: ROKU) and Shopify (NYSE: Shop) are down 68% and 74%, respectively. Roku is the most pop streaming platform in the U.South., Canada, and United mexican states as measured by viewing hours.
-
Should Y’all Buy Carnival Before It Rallies?
Carnival (NYSE: CCL) (NYSE: CUK) experienced its very worst time when the pandemic forced its ships to shore. Concerns most higher interest rates and a weakening economic system are weighing on the shares these days. Considering future prospects, should you lot purchase Carnival before it rallies?
-
Occidental Petroleum Stock Jumps As Warren Buffett Adds to $sixteen Billon Stake
Occidental Petroleum shares jumped higher Monday later on billionaire investor Warren Buffett added to both his pale in the oil major and speculation that he may be preparing to purchase at least half of its outstanding stock. Buffett boosted his holding in Occidental, which he has been calculation to for almost of the twelvemonth, to 26.8%, according to Securities & Exchange Commission filings from late last week, after buying an boosted 51.99 1000000 shares. The move came shortly after the Federal Free energy Regulatory Commission (FERC) said in late August that Berkshire Hathaway’s additional investment in Occidental was “consistent with the public interest”, giving Buffett the nod to purchase “upward to 50%” of the oil major’south mutual shares.
-
Bristol Myers Squibb rallies after FDA approves Sotyktu for psoriasis
Bristol Myers Squibb shares rose seven% in premarket trade afterward the company said the U.S. Nutrient and Drug Assistants canonical Sotyktu, which the drugmaker said was the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly ten years. Bristol Myers Squibb said the approval came after Phase 3 trials found it was more than effective compared to placebo and twice-daily Otezla, made past Amgen . Analysts at Mizuho Securities said Sotyku was approved without a and so-called black box
Source: https://finance.yahoo.com/news/symptoms-omicron-variant-south-african-185316431.html